跳至主要内容
临床试验/NCT06215300
NCT06215300招募中不适用

The Effect of Polymorphism of the GUCY1A3 rs7692387 Gene on Cardiovascular Events After Coronary Artery Bypass Grafting.

Novosibirsk Scientific Research Institute for Circulatory Pathology2 个研究点 分布在 1 个国家目标入组 800 人开始时间: 2022年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
800
试验地点
2
主要终点
myocardial infarction, acute cerebrovascular accident, death from cardiovascular causes.

研究概览

简要总结

Polymorphism in the GUCY1A3 gene worsens the activity of rCC, causing vasoconstriction and increased platelet aggregation. Studies have shown the association of the GUCY1A3 gene with the risk of coronary heart disease and its complications, with ischemic stroke

详细描述

Acetylsalicylic acid is indicated for the prevention of cardiovascular complications after CABG. Class I. The level of evidence A. ECS recommendations, Russian recommendations of cardiologists. However, the main problem of CABG remains thrombotic and thromboembolic complications in the immediate and long-term postoperative period, despite taking acetylsalicylic acid. According to various sources, the resistance to ASA among the population ranges from 5 to 45%. Resistance to ASA is primarily associated with genetic factors: the presence of polymorphisms of genes encoding platelet receptor proteins, and the functional activity of soluble guanylate cyclase (rCC), the synthesis of which is controlled by the GUCY1A3 gene. Studies have shown a link between the GUCY1A3 gene and the risk of coronary heart disease and its complications. The presence of polymorphism in the GUCY1A3 gene significantly worsens the activity of rCC, causing vasoconstriction and increased platelet aggregation. At the same time, acetylsalicylic acid cannot provide effective prevention of thrombotic and thromboembolic complications.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Stable ischemic disease 2- 4

排除标准

  • •the need to take any anticoagulants
  • •thrombocytopenia
  • •allergy to aspirin.

结局指标

主要结局

myocardial infarction, acute cerebrovascular accident, death from cardiovascular causes.

时间窗: 12 months

myocardial infarction, acute cerebrovascular accident, death from cardiovascular causes.

次要结局

未报告次要终点

研究者

发起方
Novosibirsk Scientific Research Institute for Circulatory Pathology
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

The Effect of Polymorphism of the GUCY1A3 rs7692387... | 临床试验